The only peptide of Sendai virus that is recognized by cytotoxic T lymphocytes (CTL) in B6 mice was found with (g) the use of recombinant vaccinia virus constructs containing separate genes of Sendai virus and (d) a set of overlapping peptides completely spanning the identified nudeoprotein (NP) gene product. This immunodominant NP peptide is recognized by Sendai virus-specific CTL that are known to have therapeutic effects in vivo. By subcutaneous i'mmunization, this peptide induced Sendai virus and NP peptide-specific CTL memory responses in vivo. Most importantly, mice that had been immunizd with this peptide were protected against a lethal virus dose, indicating that viral peptides can be used as antiviral T-cell vaccines. The induction of T-cell memory by free peptide immunization potentially has wide applicability in biology and medicine, including protection against infectious disease.
ABSTRACT
The only peptide of Sendai virus that is recognized by cytotoxic T lymphocytes (CTL) in B6 mice was found with (g) the use of recombinant vaccinia virus constructs containing separate genes of Sendai virus and (d) a set of overlapping peptides completely spanning the identified nudeoprotein (NP) gene product. This immunodominant NP peptide is recognized by Sendai virus-specific CTL that are known to have therapeutic effects in vivo. By subcutaneous i'mmunization, this peptide induced Sendai virus and NP peptide-specific CTL memory responses in vivo. Most importantly, mice that had been immunizd with this peptide were protected against a lethal virus dose, indicating that viral peptides can be used as antiviral T-cell vaccines. The induction of T-cell memory by free peptide immunization potentially has wide applicability in biology and medicine, including protection against infectious disease. Antiviral cytotoxic T lymphocytes (CTL) recognize short peptides derived from viral proteins when bound to major histocompatibility complex class I molecules (1) .
Such virus-specific CTL are crucially important in the resistance against many virus infections, including lymphocytic choriomeningitis virus (2, 3), influenza virus (4) (5) (6) , herpes simplex virus type 1 (7), and Sendai virus (8) . The elicitation of virus-specific CTL responses is best achieved in vivo by immunization with attenuated virus, but this bears a certain risk of causing disease. Therefore, means are sought to induce virus-specific CTL responses in vivo with synthetic viral antigens. Recently it was demonstrated that immunization with short synthetic peptides of the influenza virus nucleoprotein (NP) can induce virus-specific CTL to the priming peptide and to the virus when these peptides are chemically modified and linked to a lipid component. Free peptides, however, failed to do so (9) . Furthermore, immunization with an unbound lymphocytic choriomeningitis virus peptide also induced a virus-specific CTL response, provided the peptide was dissolved in incomplete Freund's adjuvant (IFA) (10) . However, these studies did not show whether peptide vaccination induced protection against subsequent virus challenge. Since we have demonstrated that cloned Sendai virus-specific CTL can cure mice that are lethally infected with this virus (8), we evaluated whether protection from lethal virus infection can be achieved by vaccination with the peptide recognized by these cloned CTL.
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infected stimulator cells, 108 spleen cells in 2 ml of culture medium were incubated with 6 x 102 hemagglutination units of nonvirulent Sendai virus for 1 hr at 370C and then were washed three times. The culture medium consisted of Iscove's modified Dulbecco's medium (Flow Laboratories) supplemented with 10% fetal calf serum, penicillin (100 international units/ml), kanamycin (100 jug/ml), and 2-mercaptoethanol (20 AM). When indicated, 2 units of recombinant interleukin 2 (rIL-2) (= 10 international'units) (Eurocetus, Amsterdam) was added to the culture.
Cloned CTL. The Sendai virus-specific CTL clone Tc5 was used in this study. The establishment, culture, function, major histocompatibility complex restriction specificity (H-2Kb), and phenotype (CD4-CD8+) of this clone have been described (8) .
Cell-Mediated Cytotoxicity Assay. Various numbers of effector cells were added to 2 x 103 Na25lCrO4 (51Cr)-labeled target cells in 0.2 ml of culture medium in 96-well U-bottom plates and were incubated for 6 hr at 370C in humidified air containing 5% CO2. After incubation, the supernatant was collected. The percentage of specific 51Cr release was calculated by the formula: % specific lysis = cpm experimental well -cpm background 51Cr release cpm 2% Triton X-100 release -cpm background 51Cr release Background (medium) release was always less than 30% of maximal release. The SD of triplicate wells was always less than 5% of the specific 51Cr release. Virus-infected target cells were prepared as described above for stimulator cells, except that 107 cells were incubated with 10 hemagglutination units of virus in 100 ,ul of medium. When peptides were used to label uninfected target cells, they were present during the whole assay at a concentration of 50 ,M when the peptide was made in bulk amounts, or 0.4 jig ofpeptide was added per well when the peptide was made in the "pepscan" method (see below). When targets were infected with vaccinia virus recombinant, 5 x 106 cells were incubated with 10 plaqueforming units per cell in 5 ml of culture medium for 14 hr at 37°C in humidified air containing 5% CO2 and were washed three times.
Synthesis of Peptides. Peptides were synthesized by two methods. The first method (pepscan) has been described (13, 14) and was used with modifications as described (15) . In brief, synthesis took place on polyethylene rods onto which polymers of polyacrylic acid had been formed by radiation grafting. To permit the specific detachment of peptides after synthesis, a tripeptide sequence (Asp-Pro-Gly) was cosynthesized between the peptide and the activated polyethylene rods. After deprotection and removal on noncovalently bound impurities, acid cleavage of Asp-Pro bonds was performed by heating in 0.2 ml of 70% formic acid for 20 hr at 37°C. The solvent was removed by lyophilization. The second method to generate bulk amounts of peptides has been described (16) and was performed with slight modifications. In brief, peptides were synthesized with COOH-terminal ends on a Biosearch 9500 peptide synthesizer with the use of 4-methylbenzhydrylamine resin.
Construction of the Recombinant Vacciniia Viruses. The assembly ofgenes encoding the P/C, HN, and F Sendai virus proteins (see Results) has been described (17, 18 18 ], containing the exact 3' end flanked by a Kpn I site. S1-2 was cleaved at its 5' end at the Sma I site (nucleotide 1815 of the P gene) and recombined with 3'/2' at the unique HindIII site ofthe M gene (nucleotide 854). A full-length clone of the gene encoding NP was produced by the cloning procedure described by Vidal et al. (18) . The genes encoding M, HN, F, and NP were cloned in plasmid pSP64 and that encoding P/C was cloned in plasmid pSP65. The individual genes were then transferred to the insertion vector pGS62 (kindly provided by G. L. Smith, Cambridge University), and the vaccinia recombinants were prepared exactly as described (17) for the P/C gene. The combined results clearly indicate that the mode of peptide immunization is of crucial importance in the induc- The percentage of specific 51Cr release is the mean of three independent experiments. SV, Sendai virus. tion of virus-specific CTL memory and that best results are obtained by injecting the peptide s.c. in IFA, although the use of IFA is not an absolute prerequisite (Table 3) .
RESULTS
Protection Against Lethal Sendai Virus Infection by Peptide Vaccination. Because s.c immunization with NP-(321-336) peptide dissolved in IFA resulted in optimal induction of Sendai virus-specific CTL in vivo that could be measured 4-6 wk later in vitro (Table 3) , mice were vaccinated in this way and challenged 4-6 wk later with a lethal dose of virulent Sendai virus. The results (Fig. 1) indicate that almost all control nonimmunized mice, mice treated with IFA, and mice treated with IFA and unrelated adenovirus peptide (21) .E 40 (11) .
The data of Table 3 
